Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Sees Significant Growth in Short Interest

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totaling 108,354 shares, a growth of 265.5% from the May 31st total of 29,643 shares. Based on an average daily volume of 327,763 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the shares of the stock are sold short.

Institutional Trading of Zhengye Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of ZYBT. Citadel Advisors LLC bought a new position in shares of Zhengye Biotechnology in the third quarter worth approximately $31,000. Millennium Management LLC purchased a new position in shares of Zhengye Biotechnology in the third quarter worth $38,000. WINTON GROUP Ltd purchased a new stake in Zhengye Biotechnology during the 3rd quarter valued at $56,000. XTX Topco Ltd boosted its position in Zhengye Biotechnology by 71.4% during the 4th quarter. XTX Topco Ltd now owns 59,286 shares of the company’s stock valued at $68,000 after buying an additional 24,697 shares during the period. Finally, Geode Capital Management LLC bought a new stake in Zhengye Biotechnology in the 2nd quarter worth $174,000.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Zhengye Biotechnology from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Zhengye Biotechnology Price Performance

Zhengye Biotechnology stock opened at $0.71 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.14 and a quick ratio of 0.82. The firm has a fifty day simple moving average of $0.88 and a two-hundred day simple moving average of $1.03. Zhengye Biotechnology has a twelve month low of $0.68 and a twelve month high of $13.08.

Zhengye Biotechnology (NASDAQ:ZYBT) last announced its quarterly earnings data on Tuesday, April 28th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $3.97 million during the quarter.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.